Trials / Recruiting
RecruitingNCT03818334
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
Use of Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies, a Prospective Randomized Controlled Trial
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Hospital Israelita Albert Einstein · Academic / Other
- Sex
- All
- Age
- 1 Year – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a bone marrow graft from a matched unrelated donor in overall survival, progression free survival and cumulative incidence of acute and chronic GvHD. Thirty patients will receive cyclophosphamide while twenty patients will receive antihuman T-lymphocyte immune globulin (ATG).
Conditions
- Bone Marrow Transplant Complications
- Graft Versus Host Disease
- Infection Viral
- Engraft Failure
- Immunologic Suppression
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cyclophosphamide | Cyclophosphamide 1000 mg/flask |
| DRUG | ATG | Antihuman T-Lymphocyte Immune Globulin 25 mg/flask |
Timeline
- Start date
- 2018-11-06
- Primary completion
- 2021-11-01
- Completion
- 2026-11-01
- First posted
- 2019-01-28
- Last updated
- 2019-02-01
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT03818334. Inclusion in this directory is not an endorsement.